BeiGene posts results for zanidatamab combo trial in HER2-positive breast, gastric cancersSep 2Trial updateBeiGenetislelizumab
Jazz posts results for XYWAV sleep study; registers new zanidatamab real-world studyAug 27Weekly roundup, 2 itemsJazz PharmaceuticalsXywav
FDA approves Ziihera in two regimens for first-line HER2+ gastroesophageal cancerAug 25Regulatory decisionJazz Pharmaceuticalszanidatamab-hrii
FDA approves Ziihera-based regimens for first-line HER2+ gastroesophageal cancerAug 25Regulatory decisionBeiGeneJazz Pharmaceuticals
Zymeworks flags August 25 PDUFA date for zanidatamab, updates pipeline and Theravance timelineAug 6Quarterly updateJazz Pharmaceuticalszanidatamab-hrii
ALX Oncology posts Q2 2026 results, reaffirms mid-2027 ASPEN-09-Breast readoutAug 6Quarterly updateALX Oncology Inc.
BeOne Medicines reports Q2 2026 results, raises full-year revenue guidanceAug 5Quarterly updateBeiGenesonrotoclax
Royalty Pharma raises 2026 guidance after 14% Royalty Receipts growth in Q2Aug 5Quarterly updateRoyalty Pharma plc
Jazz Pharmaceuticals reports 2Q26 results, raises 2026 revenue guidanceAug 3Quarterly updateJazz Pharmaceuticalszanidatamab-hrii
Sign inSign in